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DsRNAs longer than 30 bp induce interferon response and global changes in gene expression proﬁle
in mammalians. 21 bp siRNA and 25/27 bp dsiRNA acting via RNA interference mechanism are used
for speciﬁc gene silencing in this class of organisms. We designed selectively 20-O-methyl-modiﬁed
42 and 63 bp anti-MDR1-siRNAs that silence the expression of P-glycoprotein and restore the sensi-
tivity of drug-resistant cancer cells to cytostatic more efﬁciently than canonical 21 bp siRNAs. We
also show that they act in a Dicer-independent mode and are devoid of immunostimulating proper-
ties. Our ﬁndings suggest that 42 and 63 bp siRNAs could be used as potential therapeutics.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
RNA interference (RNAi) is an evolutionarily conserved cellular
mechanism of sequence-speciﬁc gene silencing mediated by di-
verse classes of double-stranded RNAs [1]. Long dsRNAs inside
the cell are cleaved by the RNAse-III class nuclease Dicer into
21–23-bp dsRNAs with 2-base 30-overhangs and 50-phosphates,
termed short interfering RNA (siRNAs) and assemble into the
RNA-induced gene silencing complex (RISC) [2–4]. Because of the
outstanding potency and speciﬁcity in comparison with other
loss-of-function technologies, RNAi has quickly developed into a
potent biological tool for the speciﬁc inhibition of gene expression.
Long dsRNAs efﬁciently induce RNAi in non-mammalian
eukaryotes, but in mammalian cells, dsRNAs longer than 30 bp
activate the innate immunity system and induce global changes
in the gene expression proﬁle [5]. Tuschl and colleagues demon-
strated that short 21-bp RNA duplexes, mimicking the products
of dsRNA processing by Dicer, can be used for speciﬁc gene silenc-
ing, avoiding non-speciﬁc interferon response [3].Another approach is to use longer synthetic RNA duplexes
(typically 25–30 bp) that are substrates for Dicer [6]. These longer
duplexes are effectively processed by Dicer into short 21 bp RNA
duplexes, enter RISC and trigger RNAi [7]. Recent studies have
revealed that longer synthetic RNA duplexes effectively silenced
gene expression in many cell types without inducing interferon
response, whereas they could trigger an innate immune response
in several cell types [8]. The chemical modiﬁcations known to
prevent the recognition of longer RNA duplexes by the innate
immune system without inﬂuencing silencing activity have been
assumed [6,9]. These chemical modiﬁcations can block the
immune response and we can suppose that theoretically nothing
prevents the use of partly modiﬁed dsRNAs of any length. There-
fore, we decided to check this theory in our study using various
experiments.
In our study, we used selectively modiﬁed RNA duplexes 21, 42
and 63 bp in length targetedMDR1mRNA and examined their abil-
ity to silence the expression of the target gene and the speciﬁcity of
their action. We showed that 42 and 63 bp siRNAs induced more
effective RNAi at lower concentrations than classical 21 bp siRNA
without non-speciﬁc immune effects. To our surprise, no substan-
tial processing of dsRNAs by Dicer was detected inside the cells.
Our results remove the length limits for the design of RNAi effec-
tors, and add another example in the list of novel RNAi-inducing
molecules differing from the classical siRNA.
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2.1. siRNA synthesis and duplex annealing
Modiﬁed siRNAs were synthesised on an automatic ASM-800
DNA/RNA synthesiser (Biosset, Russia) using ribo- and
20-O-methylribo b-cyanoethyl phosphoramidites (Glen Research,
USA). The nuclease-sensitive sites in siRNAwere protected by intro-
ducing 20-O-Me-analogues of ribonucleotides. After standard
deprotection, oligoribonucleotides were puriﬁed by denaturing
polyacrylamide gel electrophoresis (PAGE) and isolated as sodium
salts. The puriﬁed oligoribonucleotides were characterised byMAL-
DI-TOF mass spectrometry on PEFLEX III (Bruker Daltonics, Ger-
many). The following siRNAs were used in the present study: a
21 bp monomer (siM) homologous to the mRNA region 557–577
of the MDR1 gene (sense strand 50-GGCUUmGACmAAGUUmGUm
AUmAUmGG-30; antisense strand 50-AUmAUmACmAACUUmGUCm
AAGCCmAA-30), the 42 bp dimer (siMDR-D) and the trimer (siMDR-
T), which contain the sequence of the monomer repeated two and
three times, respectively. The siRNA-Scr 21 bp monomer (siScr-
M), with no signiﬁcant homology to any known mRNA sequences
from mouse, rat or human (sense strand 50-CmAAGUCUCGUm
AUmGUmAGUmGGUU-30; antisense strand 50-CCmACUmACmAUm
ACGAGACUUmGUU-30), the 42 bp dimer (siScr-D) and 63 bp trimer
(siScr-T), which contain the sequence of the Scr monomer repeated
two and three times, respectively, was used as the control. siRNA
duplexes were obtained via annealing of the antisense and sense
strands at equimolar concentrations in buffer A (15 mM HEPES-
KOH pH 7.4, 50 mM potassium acetate, and 1 mMmagnesium ace-
tate) and stored at 20 C.
2.2. Cell culture and transfection
Multiple drug-resistant human cell line KB-8–5 growing in the
presence of 300 nM vinblastine was generously provided by Prof
M. Gottesman (NIH, USA). The cells were grown in Dulbecco’s mod-
iﬁed Eagle’s medium (DMEM), supplemented with 10% fetal bovine
serum (FBS), 100 U/ml penicillin, 100 lg/ml streptomycin and
0.25 lg/ml amphotericin at 37 C in a humidiﬁed atmosphere con-
taining 5% CO2/95% air. Cells in the exponential phase of growth
were plated in 96-well plates at a density of 1  103 cells/well, in
24-well plates at a density of 0.4  105 cells/well or in 6-well
plates at a density of 1.5  105 cells/well 1 day before the experi-
ment; 24 h later, cells were transfected with siRNA using Oligofec-
tamine according to the manufacturer’s protocol. Untreated cells or
those treated with Oligofectamine only were used as controls.
2.3. Real-time reverse transcription PCR (RT-PCR)
KB-8–5 cells were plated in 24-well plates (0.4  105 cells/well)
and 24 h later the cells were transfected with siRNA using Oligofec-
tamine. Total RNA was extracted from the cells using the SDS-phe-
nol method 24 and 48 h post-transfection [10]. Quantiﬁcation of
speciﬁc mRNAs by RT-PCR was done essentially as described in
[11]. The amount of mRNA of each gene was normalized to the
amount of GAPDH mRNA used as an internal standard. To assess
the expression of GAPDH gene the following primers were used:
GAPDH forward: 50-GTGAAGGTCGGAGTCAAC-30 and GAPDH re-
verse: 50-TGGAATTTGCCATGGGTG-30. The relative level of gene
expression was calculated using the Bio-Rad iQ5 2.0 software
(Bio-Rad Laboratories Inc., United States).
2.4. Western blotting
KB-8–5 cells in an exponential phase of growth were plated in
24-well plates (0.4  105 cells/well); 24 h later, the cells weretransfected with siRNAs using Oligofectamine. 4 and 6 days post-
transfection, the culture medium was removed and the cells were
lysed in 60 ll of Sample buffer (Sigma–Aldrich, USA). Western
blotting was performed as described with [12] (detailed informa-
tion in Supplementary material).
2.5. MTT assay
The number of living cells was determined after 120 or 144 h of
transfection using the colorimetric method based on the oxidation
of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide
(MTT) in the mitochondria of living cells as described in [13,14]
(detailed information in Supplementary material).
2.6. Northern blotting
KB-8–5 cells in an exponential phase of growth were plated in
6-well plates (1.5  105 cells/well); 24 h later, the cells were trans-
fected with siRNAs (200 nM) using Oligofectamine according to the
procedure recommended by the manufacturer. After incubation of
the cells with siRNAs for 24, 48 and 96 h, the culture medium was
removed and the total RNA was extracted from the cells using
mirVana miRNA Isolation Kit. Northern blotting was performed
via analogy with [15] (detailed information in Supplementary
material).3. Results
3.1. Design of siRNAs
We designed a set of siRNAs with different length (siMDR) tar-
geted to the region 557–577 nt of the human MDR1 mRNA. Previ-
ously, we have demonstrated that 21 bp siRNA targeted to this
region has the ability to efﬁciently inhibit the MDR1 expression
both at the mRNA and protein (P-glycoprotein) levels [16]. Further-
more, this siMDR is capable of reversing the multiple drug resis-
tance phenotype of cancer cells and inducing their death in the
presence of earlier tolerable concentrations of cytostatics [16].
Here we constructed longer siRNAs (42 and 63 nt in length) con-
taining the sequence of the previously studied siMDR (here and
after siMDR-M or monomer) repeated two and three times, and
designated as siMDR-D and siMDR-T or dimer and trimer, respec-
tively. siRNAs with the same lengths: 21 bp siScr-M, 42 bp siScr-D
and 63 bp siScr-T, which had no signiﬁcant homology to any
known mRNA sequences from mouse, rat or human, were used
as negative controls.
The nuclease sensitive CpA, UpA and UpG sites in siRNAs were
protected by introducing 20-O-methyl analogues of ribonucleotides
according to the algorithm, which was described by us earlier [17].
The modiﬁcations in the sites of potential Dicer cleavage were
omitted.
3.2. Long selectively 20-O-methylated siRNAs do not trigger interferon
response
It is well established that 20-OMe modiﬁcations efﬁciently
prevent the induction of interferon response by 21 bp siRNA con-
taining immunostimulation sequences [18] and 25/27 bp dsiR-
NAs [19]. We evaluated the ability of selective 20-O-methyl
modiﬁcation to prevent the induction of interferon (IFN) re-
sponse by longer siRNAs. In these experiments, the mRNA levels
of two IFN responsive genes, b-actin and protein kinase R (PKR),
were used as markers of interferon response and the level of
GAPDH mRNA was used as internal standard. Poly(I:C), a well-
known IFN inducer, was used as a positive control. The data
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Fig. 1. Expression of interferon response marker genes encoding b-actin (A) and PKR (B) measured by RT-PCR 24 h (white bars) and 48 h (black bars) after transfection of KB-
8-5 cells with siRNAs (200 nM) or poly (I:C) (250 ng/mL). The level of GAPDHmRNA was used as an internal standard. Error bars indicate the standard deviations (SD) of three
independent sets of experiments.
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creased by a factor of 4.5-fold 24 h after and 3-fold 48 h after
the transfection of KB-8–5 cells with 250 ng/mL poly(I:C), while
the expression level of b-actin mRNA was reduced by 2-fold in
the same samples. Treatment of the cells with 200 nM siMDR-
M, siMDR-D, siMDR-T or siScr-M, siScr-D, siScr-T did not signif-
icantly alter the expression of the marker genes. Thus, we can
conclude that tested siRNAs do not trigger a non-speciﬁc IFN re-
sponse in the cells.
3.3. siRNA-mediated silencing of P-glycoprotein expression
Silencing activity of the 21-, 42- and 63 bp siRNAs was com-
pared by their ability to reduce the level of P-glycoprotein using
Western blot analysis in KB-8–5 cells. Cells were treated with
increasing concentrations of siMDR-M (25–200 nM), siMDR-D
(12.5–100 nM), siMDr-T (8–66.6 nM) and 200 nM siScr-M,
100 nM siScr-D and 66.6 nM siScr-T. Concentrations of siMDR-D,
siMDR-T and siScr-D, siScr-T were selected in such a way in order
to keep the equal ‘‘dose’’ of the 21 nucleotide sequence
complementary to the target in parallel samples (here and after
‘‘dose-equivalent concentrations’’), presuming the processing ofsiMDR-D and siMDR-T into two and three molecules of siMDR-
M, respectively. The P-glycoprotein level was assayed 96 and
144 h after the treatment since the maximum reduction of P-gly-
coprotein level by siMDR-M was observed at these time points
earlier [17]. It was found (Fig. 2) that treatment with speciﬁc siR-
NAs led to a concentration-dependent decrease in the P-glycopro-
tein level. The silencing effect of siMDR-M (up to 60%) at 96 h
after transfection at concentrations of 100–200 nM was similar
to that of siMDR-D at the dose-equivalent concentrations. How-
ever, when assayed 96 h after transfection, siMDR-D at low con-
centrations (30–50% silencing) and siMDR-T across the entire
range of concentrations (40–20% silencing) induced less pro-
nounced gene silencing than siMDR-M (60% silencing) (Fig. 2).
The silencing effect was substantially increased (up to 80%) at
144 h after transfection with 100–200 nM of siMDR-M and was
comparable to that of siMDR-D and siMDR-T at dose-equivalent
concentrations. It should be noted that siMDR-T at low concentra-
tions (8–16 nM) 144 h after transfection was more active than
siMDR-D and siMDR-M: the inhibitory effect was 80%, 62% and
58% for 8 nM concentration, respectively. The P-glycoprotein level
in the KB-8–5 cells treated with 200 nM siScr-M, 100 nM siScr-D
and 66.6 nM siScr-T remained unaffected.
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Fig. 2. siRNA-mediated silencing of the P-glycoprotein in KB-8–5 cells. P-glycoprotein levels were determined by Western blot analysis 96 h (A) and 144 h (B) after
transfection with different concentrations of siRNAs. The relative P-glycoprotein level was normalised against the level of b-actin protein. Error bars indicate the standard
deviations (SD) of three independent sets of experiments.
1040 O.V. Gvozdeva et al. / FEBS Letters 588 (2014) 1037–10433.4. Silencing of MDR1 expression by siRNAs revert the multiple drug
resistance of cancer cells
Since the therapeutic goal of MDR1 gene silencing is restoration
of the sensitivity of drug-resistant cancer cells to anti-cancer drugs,
we examined the ability of anti-MDR siRNAs to decrease a number
of living cells in the presence of earlier tolerable concentrations of
vinblastine (300 nM) using the MTT assay. Cells were treated with
increasing concentrations of siMDR-M (25–200 nM), siMDR-D
(12.5–100 nM), siMDR-T (8–66.6 nM) and maximal concentrations
of the control siRNAs: 200 nM siScr-M, 100 nM siScr-D and
66.6 nM siScr-T. Amounts of living cells were estimated 122 and
144 h after transfection. The number of cells in the sample treated
with transfection reagent only was taken as 100%. The data indi-
cated that treatment with siRNAs led to concentration-dependent
cell death (Fig. 3). The treatment of KB-8–5 cells with 200 nM
siMDR-M, 100 nM siMDR-D and 66.6 nM siMDR-T caused 50%
reduction of viable cells at 122 h and the almost complete disap-
pearance of viable cells at 144 h after transfection. It should be
noted that transfection with siMDR-T resulted in the more efﬁcient
reduction of viable cell number (up to 75%) at low concentrationsafter 144 h of incubation as compared with samples treated with
siMDR-D and siMDR-M at dose-equivalent concentrations. siScr-
M, siScr-D, and siScr-T had no effect on the cell viability in the
presence of 300 nM vinblastine.
3.5. siRNA processing in the cells
dsRNAs longer than 25–30 bp are known to be efﬁciently pro-
cessed by the cellular enzyme Dicer when introduced into cells
[7]. Modiﬁcation patterns of 25–27 dsRNAs including alternating
20-OMe residues that do not span the expected Dicer cut site were
found to be compatible with intracellular processing [6]. Here, we
investigated whether the longer 42 and 63 bp selectively modiﬁed
siRNAs are processed in the cells into canonical 21 bp siRNAs and
whether the cleavage is necessary for the silencing activity. siM-
DR-M, siMDR-D and siMDR-T were transfected into KB-8–5 cells
and after 4, 24 and 48 h the cells were washed extensively to re-
move unbound siRNA; the total RNA was isolated from the cells
using the SDS-phenol method. Northern blot analysis revealed that
siMDR-D and siMDR-T remained intact inside the cells after trans-
fection for a prolonged period of time and the products of their
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Fig. 3. Amounts of living cells were analysed using MTT-assay 120 h (A) and 144 h (B) after transfection with siRNA and subsequent incubation in the presence of 300 nM
vinblastine.
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Fig. 4. Northern blot analysis of siMDR-M, siMDR-D and siMDR-T transfected into
the KB-8–5 cell line. Sense strands of siMDR-M (M) siMDR-D (D) and siMDR-T (T)
were used as controls.
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these siRNAs showed potent RNAi activity, suggesting that long
siMDR-D and siMDR-T duplexes could trigger RNAi in a processing-
independent manner.
4. Discussion
Recent reports have proven that longer duplexes (25–30 bp in
length) are processed by Dicer into 21 bp siRNAs and loaded into
RISC more efﬁciently than canonical siRNAs and demonstrate bet-
ter gene silencing [7]. It has been shown that the RNAi effector
complex containing Dicer and accessory proteins interacts with
an Argonaut protein (Ago) and actively loads the bottom strand
of the siRNA into the RISC. Such a model implies an increasedafﬁnity of Dicer and Dicer/TRBP for longer dsRNAs, as Dicer re-
quires a minimum stem length for efﬁcient cleavage [6–8,20].
Moreover, it was recently demonstrated [21] that 25–27 bp dsR-
NAs can be directly loaded into Ago2 and show better efﬁcacy as
compared with canonical 21 bp siRNAs.
Therefore, in our study, we compared the silencing activity of
21 bp siRNA with the activity of 42 and 63 bp siRNAs containing
two and three copies of the same 21 bp sequence, respectively.
The main problem in the application of the long non-modiﬁed
dsRNAs as mediators of RNAi in mammalian cells and mammalians
is the induction of interferon response and the subsequent global
changers in gene expression proﬁle [9,22,23]. Chemical modiﬁca-
tion patterns preventing the activation of innate immunity and
compatible with the Dicer cleavage were described for 27/25 bp
dsiRNA [19]. Our data revealed that 20-OMe modiﬁcation of CpA,
UpA and UpG motives in 42 bp and 63 bp siRNAs effectively pre-
vents activation of the innate immunity response and did not
change the expression levels of two key interferon response genes,
PKR and b-actin, in KB-8–5 cells. Thus, selectively modiﬁed long
dsRNAs could be used in mammalian cells for speciﬁc gene
silencing.
Gene expression assays at the protein level clearly demonstrate
the efﬁcacy and speciﬁcity of all tested anti-MDR1-siRNAs. Expo-
sure to siRNAs caused a concentration-dependent reduction of
the P-glycoprotein level. The concentration-dependent results are
consistent with our previous observations using anti-MDR1 siR-
NAs, which can effectively inhibit target gene expression at a con-
centration of 200 nM [24]. To compare the biological activity of
siRNAs with different lengths we used concentrations of the equal
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three times (dose-equivalent concentrations), presuming the pro-
cessing of siMDR-D and siMDR-T into two or three molecules of
siMDR-M, respectively.
We found that siMDR-M (IC50 23 nM) was notably more active
than siMDR-D and siMDR-T at 96 h after transfection. The biologi-
cal activity of siMDR-M exceeded that of siMDR-D (IC50 40 nM) at
low concentrations and the biological activity of siMDR-T (IC50 was
not achieved) at all of the concentrations used.
The data obtained 144 h after transfection showed that the
silencing effect of longer siMDR-T (IC50 5 nM) was more pro-
nounced than the effects of siMDR-D (IC50 10 nM) and siMDR-M
(IC50 23 nM). The inhibitory effect of siMDR-T at concentrations
of 33.3–66.6 nM measured at 144 h after transfection was similar
to that of siMDR-D and siMDR-M at dose-equivalent concentra-
tions. However, transfection of siMDR-T at low concentrations
(8–16.6 nM) resulted in signiﬁcantly more efﬁcient reduction of
P-glycoprotein level. The siRNA-mediated effect was speciﬁc since
no effect on the protein levels was observed in cells treated with
the same concentrations of siRNA with a scrambled sequence both
at 96 and 144 h after transfection.
The results that were consistent with P-glycoprotein suppres-
sion data were obtained in the experiments on KB-8–5 cell viabil-
ity. These cells are characterised by over-expression of the MDR1
gene, and have the ability to grow in the presence of 300 nM vin-
blastine. Silencing of the MDR1 gene by siRNAs induces the death
of KB-8–5 cells at concentrations of vinblastine that were previ-
ously tolerated by cells. Transfection with 50–25 nM siMDR-M re-
sulted in the more efﬁcient reduction of viable cells (up to 42%)
after 122 h of incubation as compared with siMDR-D and siMDR-
T at dose-equivalent concentrations. However, siMDR-T was found
to be substantially more effective than siMDR-D and siMDR-M
144 h after transfection when used at low concentrations: up to
75% reduction of viable cells was achieved by the samples transfec-
ted with 8 nM siMDR-T. This difference in active concentrations of
siRNAs is therapeutically relevant and demonstrates the prefer-
ence of longer selectively modiﬁed interfering RNAs.
The slow development of the silencing effect caused by siMDR-
D and siMDR-T in comparison with the effect of siMDR-M may be
related to the time required for the processing of longer siRNAs or
to the difference in the kinetics of Dicer/TRBP-mediated RISC load-
ing and direct Ago2 loading. The potential explanation for the dif-
ference in canonical siRNA versus longer siRNA gene silencing
potency may be related to the minimum length requirement of siR-
NA that can be directly loaded into Ago2 leading to bias strand
selection towards the guide strand, persistence of the guide strand
and improved guide strand gene silencing.
We compared the activity of siRNA at equal 21 bp «dose» con-
centrations, hypothetically assuming that they will be completely
processed into 21 bp duplexes inside the cells. However, the data
obtained (Fig. 4) revealed that selectively modiﬁed 42 and 63 bp
siRNAs were not cleaved by Dicer to yield detectable levels of
21 bp products when transfected into the cells and the intact anti-
sense strands were present in the cells for prolonged periods of
time (at least up to 48 h). Despite the fact that the potential sites
of cleavage in the tested siRNAs are modiﬁcation-free, the effect
may be connected to the 20-O-methyl modiﬁcations of the ﬂanking
regions of these siRNAs, which prevent the formation of degrada-
tion products. The direct comparison of our modiﬁcation patterns
with those of Dicer substrates described in [21] shows that besides
the cleavage site, the smaller part of dsiRNA, which has to be cut off
during processing, does not contain modiﬁcations. In our struc-
tures, the sequences located after the cleavage site are designed
as a copy of interfering RNA and contain modiﬁcation. We can sup-
pose that modiﬁcations in the ﬂanks can reduce the efﬁciency of
cleavage. The observed sequence-speciﬁc gene silencing can berationalised in at least two ways: ﬁrstly, the effect can be induced
by the very small quantities of processed siRNA, which are not
detectable by the Northern blot in the presence of the majority
of non-processed longer species; secondly, the ability of long
dsRNA and pre-miRNA to form the direct complexes with Ago2
[21,25] makes Dicer-independent gene silencing possible. The
latter suggestion can be supported by the recent study, where a
38 nt-long molecular structure that was not processed by Dicer,
but induced efﬁcient gene silencing via the RNAi mechanism,
was described [26]. The authors implied that longer dsRNAs can
be incorporated into an active RISC complex without Dicer pro-
cessing. The data on the comparison of the efﬁciency of siRNA ac-
tion at different time points are consistent with both explanations:
both the need of time for processing and the difference in the
kinetics of Dicer/TRBP-mediated RISC loading and direct Ago2
loading could account for the delay in the development of the
silencing effect by longer siRNA. However, taking into account
the data of Northern Blot analysis we can conclude that the delay
in the development of the silencing effect by longer siRNA is re-
lated to the difference in the kinetics of Dicer/TRBP-mediated RISC
loading and direct Ago2 loading.
In conclusion, we designed selectively modiﬁed 42 and 63 bp
anti-MDR1 dsRNAs and showed their potent RNAi activity and
speciﬁcity. These siRNAs were found to silence the expression of
P-glycoprotein and restore the sensitivity of drug-resistant cancer
cells to vinblastine more efﬁciently that canonical siRNA with the
same sequence. For this reason, we believe that these structures
could be used for the development of efﬁcient therapeutics.
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